Bayer: Seeking Reformulation
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 55 (Table of Contents)
Published: 1 Jan-2005
DOI: 10.3833/pdr.v2005.i55.734 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Bayer's recent agreement with the Dutch biotech Zilip-Pharma to develop a longer acting version of its haemophilia A treatment, Kogenate#174; (recombinant antihaemophilic factor VIII), makes considerable sense given that novel approaches to tackle the disease are to be found very early on in the development pipeline...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS